Immunex Decision On Continuing Enbrel CHF Program Awaits Data Analysis
Executive Summary
Immunex' decision on whether to continue development of Enbrel for congestive heart failure awaits a more complete analysis of the data from two halted pivotal trials.
You may also be interested in...
Wyeth Enbrel Facility On Track For Third Quarter '02; CHF Research Dropped
Wyeth-Ayerst expects to begin producing additional Enbrel (etanercept) supply in the third quarter of 2002 out of its West Greenwich, R.I. manufacturing facility, American Home Products CEO Robert Essner said at a May 16 analysts meeting in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011